Sam Chun Dang Pharm (KRX: 000250)
Who is buying Sam Chun Dang Pharm?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩122.7bn ($92M) of Sam Chun Dang Pharm, the 5th largest foreign net sale among 1828 KOSDAQ stocks. Institutions net bought ₩19.1bn ($14M) and retail investors net bought ₩96.8bn ($73M) over the same window. Foreigners were net buyers on 5 of the 20 sessions.
Foreign investors hold 2.65% of Sam Chun Dang Pharm's listed shares (KRX ownership data as of Oct 13, 2026), down from 4.8% twenty sessions earlier and 3.22% a year ago.
The stock closed at ₩210,500 on Oct 13, 2026: +27.50% over 20 sessions, -9.46% year-to-date, +3.69% over one year. The 52-week range is ₩120,000 – ₩1,233,000.
At ₩210,500 the stock trades at 931.42× trailing earnings (KRX, last completed fiscal year); no analyst consensus is available for a forward P/E.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩210,500 | ₩-1.4bn | +₩4.5bn | ₩-4.0bn |
| 2026-10-12 | ₩212,500 | ₩-31.3bn | ₩-6.6bn | +₩35.0bn |
| 2026-10-08 | ₩243,500 | ₩-7.0bn | +₩11.0bn | ₩-4.1bn |
| 2026-10-07 | ₩241,000 | ₩-40.3bn | ₩-11.2bn | +₩50.7bn |
| 2026-10-06 | ₩241,000 | ₩-6.4bn | +₩1.5bn | +₩4.3bn |
| 2026-10-02 | ₩207,000 | ₩-17.7bn | +₩2.0bn | +₩15.2bn |
| 2026-10-01 | ₩199,400 | ₩-7.0bn | +₩10.5bn | ₩-4.1bn |
| 2026-09-30 | ₩172,800 | +₩3.1bn | +₩0.7bn | ₩-4.0bn |
| 2026-09-29 | ₩166,100 | +₩0.7bn | ₩-0.9bn | +₩0.1bn |
| 2026-09-28 | ₩162,500 | ₩-4.5bn | ₩-1.5bn | +₩5.8bn |
| 2026-09-23 | ₩165,700 | +₩2.7bn | +₩0.1bn | ₩-2.8bn |
| 2026-09-22 | ₩162,600 | ₩-2.3bn | ₩-1.2bn | +₩3.9bn |
| 2026-09-21 | ₩161,700 | +₩1.3bn | +₩0.9bn | ₩-1.9bn |
| 2026-09-18 | ₩159,600 | ₩-3.3bn | ₩-0.2bn | +₩3.2bn |
| 2026-09-17 | ₩163,500 | +₩3.5bn | +₩0.9bn | ₩-4.7bn |
| 2026-09-16 | ₩156,100 | ₩-0.3bn | ₩-0.3bn | +₩0.6bn |
| 2026-09-15 | ₩157,500 | ₩-0.6bn | +₩1.3bn | ₩-0.8bn |
| 2026-09-14 | ₩157,800 | ₩-1.1bn | +₩0.1bn | +₩0.9bn |
| 2026-09-11 | ₩160,700 | ₩-5.0bn | ₩-2.0bn | +₩7.0bn |
| 2026-09-10 | ₩167,200 | ₩-6.1bn | +₩9.6bn | ₩-3.6bn |
| 2026-09-09 | ₩165,100 | +₩0.3bn | ₩-0.1bn | ₩-0.2bn |
| 2026-09-08 | ₩162,900 | +₩1.7bn | ₩-0.6bn | ₩-1.1bn |
| 2026-09-07 | ₩163,000 | +₩1.3bn | +₩0.5bn | ₩-2.3bn |
| 2026-09-04 | ₩157,000 | +₩0.9bn | +₩0.3bn | ₩-1.1bn |
| 2026-09-03 | ₩155,400 | ₩-2.1bn | ₩-0.9bn | +₩3.0bn |
| 2026-09-02 | ₩159,000 | +₩1.0bn | ₩-3.2bn | +₩2.3bn |
| 2026-09-01 | ₩165,300 | +₩0.7bn | ₩-4.6bn | +₩4.0bn |
| 2026-08-31 | ₩167,900 | ₩-1.1bn | ₩-3.7bn | +₩4.1bn |
| 2026-08-28 | ₩171,000 | +₩2.4bn | ₩-2.5bn | ₩-0.0bn |
| 2026-08-27 | ₩172,800 | +₩3.7bn | +₩0.3bn | ₩-4.0bn |
| 2026-08-26 | ₩171,100 | +₩1.7bn | ₩-1.6bn | ₩-0.1bn |
| 2026-08-25 | ₩169,600 | ₩-0.2bn | +₩0.5bn | ₩-0.4bn |
| 2026-08-24 | ₩170,100 | +₩1.9bn | +₩1.7bn | ₩-3.6bn |
| 2026-08-21 | ₩168,700 | ₩-7.2bn | ₩-2.1bn | +₩10.8bn |
| 2026-08-20 | ₩182,800 | ₩-0.8bn | +₩5.6bn | ₩-4.7bn |
| 2026-08-19 | ₩179,600 | +₩0.6bn | ₩-0.6bn | ₩-0.2bn |
| 2026-08-18 | ₩184,700 | ₩-5.2bn | ₩-4.4bn | +₩9.5bn |
| 2026-08-14 | ₩189,000 | ₩-8.8bn | ₩-3.9bn | +₩12.8bn |
| 2026-08-13 | ₩189,800 | +₩6.0bn | ₩-0.2bn | ₩-5.7bn |
| 2026-08-12 | ₩186,200 | ₩-4.4bn | +₩0.1bn | +₩4.1bn |
| 2026-08-11 | ₩191,700 | ₩-23.1bn | ₩-3.8bn | +₩26.4bn |
| 2026-08-10 | ₩188,800 | ₩-2.3bn | +₩12.6bn | ₩-10.6bn |
| 2026-08-07 | ₩164,700 | +₩4.5bn | ₩-3.7bn | ₩-0.8bn |
| 2026-08-06 | ₩165,100 | ₩-2.0bn | +₩0.8bn | +₩1.0bn |
| 2026-08-05 | ₩166,600 | ₩-2.5bn | ₩-1.5bn | +₩3.9bn |
| 2026-08-04 | ₩167,300 | ₩-1.0bn | +₩7.7bn | ₩-6.6bn |
| 2026-08-03 | ₩158,300 | +₩1.8bn | +₩1.7bn | ₩-3.7bn |
| 2026-07-31 | ₩149,600 | +₩5.8bn | +₩3.8bn | ₩-9.4bn |
| 2026-07-30 | ₩129,900 | ₩-1.5bn | +₩2.1bn | ₩-3.7bn |
| 2026-07-29 | ₩126,500 | +₩7.8bn | +₩3.4bn | ₩-11.7bn |
| 2026-07-28 | ₩139,500 | +₩3.5bn | +₩2.3bn | ₩-6.2bn |
| 2026-07-27 | ₩149,400 | +₩1.4bn | +₩6.6bn | ₩-8.1bn |
| 2026-07-24 | ₩148,800 | ₩-9.8bn | ₩-1.1bn | +₩10.8bn |
| 2026-07-23 | ₩166,100 | +₩0.4bn | +₩1.6bn | ₩-2.5bn |
| 2026-07-22 | ₩152,800 | ₩-11.4bn | ₩-5.7bn | +₩15.5bn |
| 2026-07-21 | ₩167,800 | ₩-89.5bn | ₩-19.5bn | +₩105.3bn |
| 2026-07-20 | ₩239,000 | ₩-4.5bn | ₩-3.6bn | +₩8.3bn |
| 2026-07-16 | ₩184,100 | +₩2.6bn | ₩-2.3bn | ₩-0.3bn |
| 2026-07-15 | ₩191,600 | +₩5.1bn | ₩-0.3bn | ₩-5.5bn |
| 2026-07-14 | ₩180,000 | +₩3.1bn | ₩-0.2bn | ₩-3.1bn |
| 2026-07-13 | ₩184,900 | ₩-0.9bn | ₩-1.5bn | +₩2.2bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-1.4bn | $-1M | +₩4.5bn | ₩-4.0bn |
| 5 days | ₩-86.3bn | $-65M | ₩-0.8bn | +₩82.0bn |
| 20 days | ₩-122.7bn | $-92M | +₩19.1bn | +₩96.8bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Sam Chun Dang Pharm stock?
Over the last 5 sessions foreign investors net sold ₩86.3bn ($65M) of Sam Chun Dang Pharm; over 60 sessions they net sold ₩242.2bn ($182M); since Jan 1, 2026 they net bought ₩209.4bn ($157M). Over 20 sessions the stock is the 5th largest foreign net sale among 1828 KOSDAQ stocks.
How much of Sam Chun Dang Pharm do foreign investors own?
Foreign investors own 2.65% of Sam Chun Dang Pharm's shares as of Oct 13, 2026, versus 3.22% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net bought ₩19.1bn ($14M) and retail investors net bought ₩96.8bn ($73M) of Sam Chun Dang Pharm. Foreign selling is being absorbed mainly by retail buying.
Is Sam Chun Dang Pharm listed on KOSPI or KOSDAQ?
Sam Chun Dang Pharm (삼천당제약) trades on KOSDAQ under KRX code 000250 in the Biotech & Pharma group, with a market capitalization of ₩5T ($3.7B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩193bn ($145M) | – | ₩10bn ($7M) | -₩4bn (-$3M) |
| 2024 | ₩211bn ($158M) | +9.50% | ₩3bn ($2M) | -₩5bn (-$4M) |
| 2025 | ₩232bn ($174M) | +9.90% | ₩8bn ($6M) | ₩12bn ($9M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.